Skip to content

Study · Systematic review · 2024

5 results

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.

Rivera FB, Lumbang GNO, Gaid DRM, Cruz LLA, Magalong JV, Bantayan NRB, Lara-Breitinger KM, Gulati M, Bakris G

Diabetes, obesity & metabolism20 Mar 2024Cited by 42 (Europe PMC)

PMID38505997 (opens in a new tab)DOI10.1111/dom.15529 (opens in a new tab)PepBankPUB-38505997
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In placebo-controlled trials, semaglutide reduced systolic blood pressure versus placebo (mean difference -3.40 mmHg).

    In plain wordsIn placebo-controlled trials, semaglutide lowered systolic blood pressure modestly compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference in SBP
    −3.4 mmHg
    semaglutide vs placebo

    Source sentences

    Summary
    semaglutide: MD -3.40 (95% CI -4.22 to -2.59, p < .001
    1 context sentence
    Summary · context
    A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023.
  2. 02HumanSystematic reviewEfficacy outcome

    In placebo-controlled trials, liraglutide reduced systolic blood pressure versus placebo (mean difference -2.61 mmHg).

    In plain wordsIn placebo-controlled trials, liraglutide lowered systolic blood pressure modestly compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference in SBP
    −2.61 mmHg
    liraglutide vs placebo

    Source sentences

    Summary
    liraglutide: MD -2.61 (95% CI -3.48 to -1.74, p < .001
    1 context sentence
    Summary · context
    A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023.
  3. 03HumanSystematic reviewEfficacy outcome

    In placebo-controlled trials, the diastolic blood pressure reduction with semaglutide was not significant; only exenatide showed a significant reduction.

    In plain wordsIn placebo-controlled trials, semaglutide did not significantly lower diastolic blood pressure compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiastolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Diastolic BP reduction was only significant in the exenatide group [MD -0.94 (95% CI -1.78 to -0.1), p = .03].
    1 context sentence
    Summary · context
    A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023.
  4. 04HumanSystematic reviewEfficacy outcome

    In placebo-controlled trials, the diastolic blood pressure reduction with liraglutide was not significant; only exenatide showed a significant reduction.

    In plain wordsIn placebo-controlled trials, liraglutide did not significantly lower diastolic blood pressure compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiastolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Diastolic BP reduction was only significant in the exenatide group [MD -0.94 (95% CI -1.78 to -0.1), p = .03].
    1 context sentence
    Summary · context
    A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023.
  5. 05HumanSystematic reviewMechanism

    Among semaglutide cohorts, larger falls in HbA1c and body mass index were directly associated with larger systolic blood pressure reduction.

    In plain wordsIn semaglutide trials, larger falls in HbA1c and body mass index were linked to larger drops in systolic blood pressure.

    Peptide
    Semaglutide
    Outcome
    Not applicableAssociation of HbA1c and BMI changes with SBP reduction
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Among semaglutide cohorts, mean changes in glycated haemoglobin and mean changes in body mass index were directly associated with SBP reduction.
    1 context sentence
    Summary · context
    A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    9 Oct 2026, 18:17 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.